- Home
- NTHI vs TLSA Comparison
NTHI vs TLSA Comparison
Compare NTHI & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NTHI | TLSA |
|---|---|---|
| Founded | 2008 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 195.5M | 200.8M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | NTHI | TLSA |
|---|---|---|
| Price | $10.19 | $1.77 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 68.0K | ★ 289.8K |
| Earning Date | 11-14-2025 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $59,990.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.20 | $0.63 |
| 52 Week High | $25.00 | $2.60 |
Technical Indicators
Market Signals| Indicator | NTHI | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 58.54 | 50.49 |
| Support Level | $8.63 | $1.62 |
| Resistance Level | $9.75 | $1.82 |
| Average True Range (ATR) | 0.88 | 0.14 |
| MACD | 0.23 | 0.01 |
| Stochastic Oscillator | 95.59 | 60.84 |
Price Performance
Historical ComparisonAbout NTHI NeOnc Technologies Holdings Inc.
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA).
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.